Pathology: mBC - TNBC - L1 - all population;
| mBC - TNBC - L1 - all population | ||||
| IMpassion-130 (all population), 2018 | IMpassion-131 (all population), 2020 | KEYNOTE-355 (all population), 2020 | ||
| atezolizumab plus paclitaxel | 1 | T1 | ||
| pembrolizumab plus SoC | 1 | T1 | ||
| atezolizumab plus nab-paclitaxel | 1 | T1 | ||
| placebo plus SoC | 0 | T0 | ||
| Standard of Care (SoC) | 0 | T0 | T0 | |